On August 20, PHARMARON rose 7.57% in regular trading, trading at 33.3 HKD/share, with turnover of approximately 50.68 million HKD.

On the news front, the company's board convened today to review and approve its interim results for the first half of the year. Previously, PHARMARON guided H1 revenue of 7.472 billion to 7.665 billion yuan, representing year-over-year growth of 16%-19%. New order signings grew over 30% year-over-year, with small molecule CDMO new orders surging more than 50%. Attributable net profit is expected to increase 4%-10%, reflecting strong earnings visibility.

Meanwhile, the CXO sector rallied broadly, with peers GenScript Biotech up 10.9%, XtalPi up 11.96%, Insilico up 8.27%, and WuXi Biologics up 3.67%. Sustained industry prosperity combined with concentrated H1 earnings delivery is accelerating sector valuation recovery. Additionally, JPMorgan recently increased its stake in PHARMARON by approximately 1.29 million shares at around 22.11 HKD per share, signaling institutional confidence.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)